Mokari Atabak, Chief Financial Officer of Corcept Therapeutics (CORT), has filed 36 Form 4 transactions, all concentrated in that single company. The pattern is decisively one-sided: 21 open-market sales totaling roughly $18.7 million, with zero open-market purchases. The selling has been aggressive and sustained, occurring in clustered batches on June 15, July 15, and July 30, 2026. The largest single-day disposition came on July 30, when Atabak executed 13 separate "S" transactions worth approximately $9.1 million, including individual sales ranging from $43,384 to $1.78 million. The July 15 cluster added another $3.5 million in sales, while the June 15 tranche contributed $3.2 million.
The selling is intertwined with option exercises, which account for the only non-sale activity. Atabak exercised options on each of the three trading dates, acquiring shares worth a combined $3.48 million (including a $1.84 million exercise on July 30), but these "M" transactions are mechanical conversions rather than conviction buys. The subsequent "S" filings show those acquired shares being immediately liquidated, a standard exercise-and-sell pattern. Notably, there are no "P" codes—no open-market purchases—anywhere in the filing history, and no gifts or tax-withholding events. The data reveals a CFO who has been steadily monetizing equity compensation over a six-week window, with the pace accelerating in late July. The total acquired value of $87,415.89 from grants is dwarfed by the $18.7 million in sales, underscoring a clear directional bias toward distribution rather than accumulation.
AI-assisted summary